alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Editorial Note on Part 201
Editorial Note: Nomenclature changes to part 201 appear at 69 FR 13717, Mar. 24, 2004.

§ 201.308 Ipecac syrup; warnings and directions for use for over-the-counter sale. ( a ) It is estimated that each year about 500,000 accidental poisonings occur in the United States and result in approximately 1,500 deaths, of which over 400 are children. In the emergency treatment of these poisonings, ipecac syrup is considered the emetic of choice. The immediate availability of this drug for use in such situations is critical, since rapid treatment may be the difference between life and death. The restriction of this drug to prescription sale limits its availability in emergencies. On the other hand, it is the consensus of informed medical opinion that ipecac syrup should be used only under medical supervision in the emergency treatment of poisonings. In view of these facts, the question of whether ipecac syrup labeled as an emergency treatment for use in poisonings should be available over the counter has been controversial.
( b ) In connection with its study of this problem, the Food and Drug Administration has obtained the views of medical authorities. It is the unanimous recommendation of the American Academy of Pediatrics, the American Association of Poison Control Centers, the American Medical Association, and the Medical Advisory Board of the Food and Drug Administration that ipecac syrup in 1 fluid ounce containers be permitted to be sold without prescription so that it will be readily available in the household for emergency treatment of poisonings, under medical supervision, and that the drug be appropriately packaged and labeled for this purpose.
( c ) In view of the above recommendations, the Commissioner of Food and Drugs has determined that it is in the interest of the public health for ipecac syrup to be available for sale without prescription, provided that it is packaged in a quantity of 1 fluid ounce (30 milliliters), and its label bears, in addition to other required label information, the following, in a prominent and conspicuous manner: ( 1 ) A statement conspicuously boxed and in red letters, to the effect: “For emergency use to cause vomiting in poisoning. Before using, call physician, the Poison Control Center, or hospital emergency room immediately for advice.”
( 2 ) A warning to the effect: “Warning—Keep out of reach of children. Do not use in unconscious persons. Ordinarily, this drug should not be used if strychnine, corrosives such as alkalies (lye) and strong acids, or petroleum distillates such as kerosine, gasoline, coal oil, fuel oil, paint thinner, or cleaning fluid have been ingested.”
( 3 ) Usual dosage: 1 tablespoon (15 milliliters) in persons over 1 year of age.
#### § 211.89 Rejected components, drug product containers, and closures.

Rejected components, drug product containers, and closures shall be identified and controlled under a quarantine system designed to prevent their use in manufacturing or processing operations for which they are unsuitable.
II 

109TH CONGRESS 

1ST SESSION S. 1027 

To exempt the natural aging process in the determination of the production 

period for distilled spirits under section 263A of the Internal Revenue 

Code of 1986. 

IN THE SENATE OF THE UNITED STATES 

MAY 12, 2005 

Mr. BUNNING introduced the following bill; which was read twice and referred 

to the Committee on Finance 

A BILL

To exempt the natural aging process in the determination 

of the production period for distilled spirits under section 

263A of the Internal Revenue Code of 1986.

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. EXEMPTION OF NATURAL AGING PROCESS IN 

4 DETERMINATION OF PRODUCTION PERIOD 

5 FOR DISTILLED SPIRITS UNDER SECTION 

6 263A. 

7 (a) IN GENERAL.—Section 263A(f) of the Internal 

8 Revenue Code of 1986 (relating to general exceptions) is 
2

•S 1027 IS

1 amended by adding at the end the following new para2 graph: 

3 ‘‘(5) EXEMPTION OF NATURAL AGING PROCESS

4 IN DETERMINATION OF PRODUCTION PERIOD FOR

5 DISTILLED SPIRITS.—For purposes of this sub6 section, the production period for distilled spirits 

7 shall be determined without regard to any period al8 located to the natural aging process.’’. 

9 (b) EFFECTIVE DATE.—The amendment made by 

10 this section shall apply to production periods beginning 

11 after the date of the enactment of this Act.

Æ
Editorial Note on Part 172
Editorial Note: Nomenclature changes to part 172 appear at 61 FR 14482, Apr. 2, 1996; 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; 68 FR 15355, Mar. 31, 2003; 70 FR 40880, July 15, 2005; 70 FR 67651, Nov. 8, 2005; 70 FR 72074, Dec. 1, 2005; and 81 FR 49896, July 29, 2016.

§ 172.831 Sucralose. ( a ) Sucralose is the chemical 1,6-dichloro-1,6-dideoxy-β-D-fructofuranosyl-4-chloro-4-deoxy-α-D-galactopyranoside (CAS Reg. No. 56038-13-2).
( b ) The additive meets the specifications of the Food Chemicals Codex, 7th ed. (2010), pp. 993-995, which is incorporated by reference. The Director of the Office of the Federal Register approves this incorporation by reference in accordance with 5 U.S.C. 552(a) and 1 CFR part 51. You may obtain copies from the United States Pharmacopeial Convention, 12601 Twinbrook Pkwy., Rockville, MD 20852 (Internet address *http://www.usp.org*). Copies may be examined at the Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, 240-402-7500, between 9 a.m. and 4 p.m., Monday through Friday, or at the National Archives and Records Administration (NARA). For information on the availability of this material at NARA, call 202-741-6030 or go to: *http://www.archives.gov/federal-register/cfr/ibr-locations.html .*
( c ) The additive may be used as a sweetener in foods generally, in accordance with current good manufacturing practice in an amount not to exceed that reasonably required to accomplish the intended effect.
( d ) If the food containing the additive purports to be or is represented to be for special dietary use, it shall be labeled in compliance with part 105 of this chapter.
[63 FR 16433, Apr. 3, 1998, as amended at 64 FR 43909, Aug. 12, 1999; 78 FR 14665, Mar. 7, 2013; 78 FR 71464, Nov. 29, 2013; 88 FR 17721, Mar. 24, 2023]
Editorial Note on Part 189
Editorial Note: Nomenclature changes to part 189 appear at 61 FR 14482, Apr. 2, 1996; 66 FR 56035, Nov. 6, 2001; 70 FR 40880, July 15, 2005; and 70 FR 67651, Nov. 8, 2005.

§ 189.280 4,4′-Methylenebis (2-chloroanaline). ( a ) 4,4′-Methylenebis (2-chloroanaline) has the molecular formula, C13H12Cl2N2. It is a synthetic chemical not found in natural products and has been used as a polyurethane curing agent and as a component of food packaging adhesives and polyurethane resins.
( b ) Food containing any added or detectable level of this substance is deemed to be adulterated in violation of the act based upon an order published in the Federal Register of December 2, 1969 (34 FR 19073).
### RE: One more modeling question. and updates to Indiana's Lead Emissions BA TE S, JON to

: And y Chang
Cc : "W olff, Brian", "RITTER, KEN", "Sherman, Steven", "PEDERSEN, CHRISTINE"

From: "BATES, JON" <JBATES@idem.IN.gov> To: Andy Chang/R5/USEPA/US@EPA Cc: "W olff, Brian" <BWO LFF@idem.IN.gov>, "RITTER, KEN" <KRITTER@idem.IN.gov>,

"Sherman, Steven" <SSHERMAN@idem.IN.gov>, "PEDERSEN, CHRISTINE" <CPEDERSE@idem.IN.gov> In response to the modeling questions, actua l 2007 TRI emissions were used, and if “re - entrainment of dust” means vehicle traffic then no, this was not factored into the analysis. Please let me know if you have any questions. Jon Bates IDEM Office of Air Quality (317) 233 -4226



### RE: Quic k Question about Muncie Lead Modeling Sherman, Steven to

: And y Chang

From: "Sherman, Steven" <SSHERMAN@idem.IN.gov> To: Andy Chang/R5/USEPA/US@EPA 

### That’s right; 2007 TRI emissions with 1992 meteorology. From: Ch ang.Andy@epamail.epa.gov [mailto:Chang.Andy@epamail.epa.gov] Sent: Tuesday, June 01, 2010 12:33 PM To: Sherman, Steven Subject: RE: Quick Question about Muncie Lead ModelingHi Steve,

Thanks for the response. To be clear: this entire map, including t he maximum modeled impact and the colored contours was based on the highest monthly average in 1992? I remember a conversation with IDEM where you all indicated that 2007 TRI emissions were used for air dispersion modeling; can you clarify this for me? Thanks again.

************************************************************* We ian 'Andy' Chang Environmental Engineer US EPA Region 5 Air and Radiation Division 77 W . Jackson Blvd AR- 18J Chicago, IL 60604 312.886.0258 (direct) 312.697.2639 (fax
Editorial Note on Part 184
Editorial Note: Nomenclature changes to part 184 appear at 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; 68 FR 15355, Mar. 31, 2003; 69 FR 13717, Mar. 24, 2004; 70 FR 40880, July 15, 2005; 70 FR 67651, Nov. 8, 2005; and 81 FR 49897, July 29, 2016.

§ 184.1985 Aminopeptidase enzyme preparation derived from lactococcus lactis. ( a ) Aminopeptidase enzyme preparation is derived from the nonpathogenic and nontoxicogenic bacterium *Lactococcus lactis* (previously named *Streptococcus lactis*). The preparation contains the enzyme aminopeptidase (CAS Reg. No. 9031-94-1; EC 3.4.11.1) and other peptidases that hydrolyze milk proteins. The preparation is produced by pure culture fermentation.
( b ) The ingredient meets the specifications for enzyme preparations in the Food Chemicals Codex, 3d ed. (1981), pp. 107-110, which are incorporated by reference in accordance with 5 U.S.C. 552(a) and 1 CFR part 51. Copies are available from the National Academy Press, 2101 Constitution Ave. NW., Washington, DC 20418, or may be examined at the Office of Food Additive Safety (HFS-200), Center for Food Safety and Applied Nutrition, Food and Drug Administration, 5001 Campus Dr., College Park, MD 20740, 240-402-1200, or at the National Archives and Records Administration (NARA). For information on the availability of this material at NARA, call 202-741-6030, or go to: *http://www.archives.gov/federal_register/code_of_federal_regulations/ibr_locations.html .*
( c ) In accordance with § 184.1(b)(1), the ingredient is used in food with no limitations other than current good manufacturing practice. The affirmation of this ingredient as generally recognized as safe as a direct human food ingredient is based upon the following current good manufacturing practice conditions of use: ( 1 ) The ingredient is used as an enzyme, as defined in § 170.3(o)(9) of this chapter, as an optional ingredient for flavor development in the manufacture of cheddar cheese, in accordance with § 133.113 of this chapter, and in the preparation of protein hydrolysates.
( 2 ) The ingredient is used at levels not to exceed current good manufacturing practice.
[60 FR 54193, Oct. 20, 1995, as amended at 78 FR 14667, Mar. 7, 2013]
```

[Federal Register Volume 80, Number 102 (Thursday, May 28, 2015)]
[Notices]
[Page 30539]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-12921]

-----------------------------------------------------------------------

DEPARTMENT OF TRANSPORTATION

Office of the Secretary

National Freight Advisory Committee

ACTION: Announcement of Charter Renewal for the National Freight 
Advisory Committee.

-----------------------------------------------------------------------

SUMMARY: This notice announces renewal of National Freight Advisory 
Committee's charter for a period of 1 year (NFAC), effective May 28, 
2015. The NFAC will provide information, advice, and recommendations to 
the U.S. Secretary of Transportation on matters relating to U.S. 
freight transportation.

FOR FURTHER INFORMATION CONTACT: Maria Lefevre, Designated Federal 
Officer at (202) 366-1999 or freight@dot.gov or visit the NFAC Web site 
at www.dot.gov/nfac.

SUPPLEMENTARY INFORMATION: Pursuant to Section 10(a)(2) of the Federal 
Advisory Committee Act (Pub. L. 92-463), DOT is giving notice of the 
charter renewal for the NFAC. The NFAC is established under the 
authority of the U.S. Department of Transportation, in accordance with 
the provisions of the Federal Advisory Committee Act (5 U.S.C. App. 2). 
The NFAC shall continue to undertake information-gathering activities, 
develop technical advice, and present recommendations to the Secretary 
to further inform this policy, including but not limited to 
implementation of the freight provisions of the Moving Ahead for 
Progress in the 21st Century Act (MAP-21), Public Law 112-141, and 
other issues of freight transportation policy and programs, including 
legislative recommendations. The NFAC is composed of up to 50 members 
representing diverse modes of transportation; regional representation 
across the Nation; relevant policy areas such as safety, labor, 
environment; freight customers and providers; and government bodies. 
The diversity of the Committee ensures the requisite range of views and 
expertise necessary to fulfill its responsibilities.

    Issued: May 21, 2015.
Anthony R. Foxx,
Secretary.
[FR Doc. 2015-12921 Filed 5-27-15; 8:45 am]
 BILLING CODE 4910-9X-P
```
<TABLE> <S> <C>

<ARTICLE> 9
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM FRONTIER
FINANCIAL CORPORATION AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH 10Q.
</LEGEND>
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-1997
<PERIOD-START>                             JAN-01-1997
<PERIOD-END>                               MAR-31-1997
<CASH>                                          33,551
<INT-BEARING-DEPOSITS>                           3,550
<FED-FUNDS-SOLD>                                45,610
<TRADING-ASSETS>                                     0
<INVESTMENTS-HELD-FOR-SALE>                     90,580
<INVESTMENTS-CARRYING>                          33,277
<INVESTMENTS-MARKET>                            33,866
<LOANS>                                        616,819
<ALLOWANCE>                                   (13,503)
<TOTAL-ASSETS>                                 832,572
<DEPOSITS>                                     697,322
<SHORT-TERM>                                    13,533
<LIABILITIES-OTHER>                              7,969
<LONG-TERM>                                     30,092
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                        71,134
<OTHER-SE>                                      12,522
<TOTAL-LIABILITIES-AND-EQUITY>                 832,572
<INTEREST-LOAN>                                 15,450
<INTEREST-INVEST>                                2,445
<INTEREST-OTHER>                                     0
<INTEREST-TOTAL>                                17,895
<INTEREST-DEPOSIT>                               7,238
<INTEREST-EXPENSE>                               7,775
<INTEREST-INCOME-NET>                           10,120
<LOAN-LOSSES>                                    (100)
<SECURITIES-GAINS>                                   0
<EXPENSE-OTHER>                                  4,436
<INCOME-PRETAX>                                  6,376
<INCOME-PRE-EXTRAORDINARY>                       4,175
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                     4,175
<EPS-PRIMARY>                                      .57
<EPS-DILUTED>                                      .57
<YIELD-ACTUAL>                                    5.37
<LOANS-NON>                                      3,516
<LOANS-PAST>                                         0
<LOANS-TROUBLED>                                   118
<LOANS-PROBLEM>                                      0
<ALLOWANCE-OPEN>                                13,268
<CHARGE-OFFS>                                       73
<RECOVERIES>                                       208
<ALLOWANCE-CLOSE>                               13,503
<ALLOWANCE-DOMESTIC>                            13,503
<ALLOWANCE-FOREIGN>                                  0
<ALLOWANCE-UNALLOCATED>                              0
        

</TABLE>
<PAGE>   1
[LOGO]

                      Securities & Exchange Act 1934 registration number 0-22617
                                                                 TSE & VSE : MMM

                                  NEWS RELEASE


FOR IMMEDIATE RELEASE: JANUARY 14, 1999

VANCOUVER, BRITISH COLUMBIA - Minco Mining & Metals Corporation is pleased to
announce that it has signed a subscription agreement with Arbora Portfolio
Management of Zurich, Switzerland, for a private placement of 250,000 units at a
price of $0.85 per unit. Each unit consists of one common share of the Company
and half (1/2) a share purchase warrant. Each one full share purchase warrant
will entitle the holder to purchase one additional share of the Company at the
price of $0.85 per share for a period of one year from the date of closing of
the Private Placement. Proceeds from the Private Placement will be used for
general corporate purposes.

The Private placement is subject to regulatory approval.

                                     - 30 -

  For further information, please contact: Dr. Ken Z. Cai, President & CEO, or
   Christine Reynolds, Investor Relations Telephone: 1-888-288-8288 or (604)
          688-8002; Fax: (604) 688-8030; Website: www.minco-mining.com

 The Toronto and Vancouver Stock Exchanges have not reviewed and do not accept
              responsibility for the accuracy of this news release
<PAGE>   1
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549


                                    FORM 8-K
                                 CURRENT REPORT


                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934



Date of Report (Date of earliest event reported) March 31, 1999

                              THE LOEWEN GROUP INC.
             (Exact name of registrant as specified in its charter)



<TABLE>
<S>                                  <C>                         <C>          
    British Columbia, Canada                 0-18429                        98-0121376   
-------------------------------      ------------------------    ---------------------------------
(State or other jurisdiction of      (Commission File Number)    (IRS Employer Identification No.)
         incorporation)
</TABLE>




     4126 Norland Avenue, Burnaby, British Columbia            V5G 3S8
     -----------------------------------------------------------------
        (Address of principal executive offices)             (zip code)



Registrant's telephone number, including area code      604-299-9321
                                                   ------------------------



                                       N/A
          (Former name or former address, if changed since last report)




                                                      Exhibit Index is on page 3
                                                                     Page 1 of 6


<PAGE>   2
ITEM 5. OTHER EVENTS.

Pursuant to Form 8-K, General Instructions F, registrant hereby incorporates by
reference the press release attached hereto as Exhibit 99.


ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.

        Exhibit No.   Description

        Exhibit 99    The Loewen Group Inc. Press Release dated March 31, 1999


                                   SIGNATURES

               Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.

Dated: April 1, 1999

                                 THE LOEWEN GROUP INC.



                                 By: /s/ BRADLEY D. STAM
                                    -------------------------------
                                 Name:  Bradley D. Stam
                                 Title: Senior Vice President, Law


<PAGE>   3
                                  EXHIBIT INDEX


<TABLE>
<CAPTION>
                                                                                  Sequential
Number         Exhibit                                                            Page Number
------         -------                                                            -----------
<S>            <C>                                                                <C>
99             The Loewen Group Inc.                                                   4
               Press Release dated March 31, 1999
</TABLE>
<PAGE>
 
                                                                      Exhibit 11

                       COMPUTATION OF EARNINGS PER SHARE
                      GULF STATES STEEL, INC. OF ALABAMA

<TABLE> 
<CAPTION> 
                                                               Fiscal Year         Fiscal Year       For the period
                                                                  Ended               Ended          April 21, 1995
                                                               October 31,          October 31,      to October 31,
                                                               -----------          -----------      --------------
                                                                   1997                1996               1995
                                                                   ----                ----               ----
<S>                                                           <C>                  <C>                <C> 
Net income (loss) before cumulative effect of
    accounting change                                          $(15,851,000)       $  (370,000)         $ 1,245,000

Cumulative effect of accounting change                           (2,647,000)                --                   --
                                                               ------------        -----------          -----------
Net income (loss)                                              $(18,498,000)       $  (370,000)         $ 1,245,000
                                                               ============        ===========          ===========
                                                              
Shares:
    Weighted average common shares outstanding                    3,610,000          3,610,000            3,610,000

    Net effect of dilutive put warrants and stock
       options based on the treasury stock method                       N/A                N/A              189,838
                                                               ------------        -----------          -----------
    Weighted average common and common
        equivalent shares outstanding                             3,610,000          3,610,000            3,799,838
                                                               ============        ===========          ===========
Net income (loss) per share before cumulative
    effect of accounting change                                $      (4.39)       $      (.10)         $       .33

Cumulative effect of accounting change                                 (.73)                 --                  --
                                                               ------------        -----------          -----------
                                                          

Net income (loss) per share                                    $      (5.12)       $      (.10)         $       .33
                                                               ============        ===========          ===========
</TABLE> 
                                                                              1